HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No Regulatory Imprimatur In UK For Scottish Firm’s Hangover Remedy Claim

Executive Summary

Bounce Back Drinks sought to establish its bona fides as a registered consumer product provider, but statements referencing ASA, EFSA and MHRA imply the agencies reviewed and approved its product and advertising. Plus, hangover remedy claims are prohibited under UK regulations.

You may also be interested in...



Hangover Cures Might Work, But Evidence Weak – Study

According to a recent systematic review of evidence from randomised placebo-controlled trials, the claimed hangover-reducing effects of traditional herbal medicines and dietary supplement ingredients do have some scientific backing. However, the quality of the evidence is extremely low. 

Widely Available Unapproved Hangover Remedies Concern US FDA As Encouraging Overindulgence

As CFSAN warned seven marketers, supplement products from numerous other businesses advertised as hangover remedies, or as formulations to prevent symptoms associated with overindulgence, remained available to US consumers. Like one business FDA warned, numerous companies are offering OTC intravenous treatments for hangovers, available at locations accepting walk-in or by-appointment customers.

EPH Warned On Opioid Treatment Claim For Enzyme, Amino, Peptide Blend

EPH Technologies apparently heeds FDA's warning, which also noted violative drug and disease claims for nasal sprays. EPH continued selling other supplements on 2 December, but the three that FDAcited in 18 November warning were not available.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS149632

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel